Acne Drugs Market Size, Share & Trends Analysis Report By Type, By Therapeutic Class (Retinoid, Antibiotic, Combination), By Mode of Administration (Injectable, Topical, Oral), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List to Data Sources
1.4 List of Abbreviations
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Forms
3.1.2 Causative Factors and Triggers
3.1.3 Degree of Severity
3.2 Epidemiology
3.3 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
3.4 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
Chapter 4 Global Acne Drugs Market Overview
4.1 Introduction and Market Overview
4.1.1 Segmentation, by type
4.1.1.1 Comedonal
4.1.1.2 Inflammatory
4.1.1.3 Cystic
4.1.1.4 Post-Surgical/wound
4.1.2 Segmentation, by therapeutic class
4.1.2.1 Retinoid
4.1.2.2 Antibiotic
4.1.2.3 Hormonal Agent
4.1.2.4 Combination
4.1.2.5 Others
4.1.3 Segmentation, by mode of administration
4.1.3.1 Topical
4.1.3.2 Oral
4.1.3.3 Injectable
4.1.4 Segmentation, by major market
4.1.4.1 U.S.
4.1.4.2 EU5
4.1.4.3 Japan
4.1.5 Market size and forecast
4.1.6 Sales performance
4.1.7 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 Deals Landscape (2013-2018)
4.5 Pricing and Reimbursement
4.6 Emerging Markets
4.6.1 India
4.6.2 South Korea
4.6.3 Brazil
4.6.4 Mexico
4.7 SWOT Analysis
Chapter 5 Acne Drugs Market: Pipeline Intelligence
5.1 Pipeline Landscape
5.1.1 Drugs under Development
5.2 Key R&D Trends
5.2.1单克隆抗体
5.2.2 Stearoyl-CoA desaturase
5.2.3 Melanocortin Receptor Antagonist
5.3 Late-Stage Pipeline
5.4 Profile of Disruptive Drugs
5.4.1 Seysara
5.4.2 CJM112
5.4.3 FMX-101
5.4.4 TWIN (S6G5T-1, S6G5T-3)
Chapter 6 Company Profiles
6.1 Allergan
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales
6.1.4 Company - key news flow
6.1.5 Pipeline View
6.1.6 Pipeline Forecast
6.1.7 Catalysts and Event Calendar
6.1.8 SWOT Analysis
6.2 Bayer
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales
6.2.4 Company - key news flow
6.2.5 SWOT Analysis
6.3 Galderma S.A.
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales
6.3.4 Company - key news flow
6.3.5 Pipeline View
6.3.6 Pipeline Forecast
6.3.7 SWOT Analysis
6.4 Stiefel
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales
6.4.4 Company - key news flow
6.4.5 SWOT Analysis
6.5 Valeant
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales
6.5.4 Company - key news flow
6.5.5 Pipeline View
6.5.6 Pipeline Forecast
6.5.7 Catalysts and Event Calendar
6.5.8 SWOT Analysis
Chapter 7 Market Outlook
7.1 Winners and Losers
7.2 Emerging Companies
7.3 What the Future Holds

List of Tables

Table 1 List of Abbreviation
Table 2 Acne Prevalence and Incidence Rates - 2017 (in %)
Table 3 Forecast Acne Prevalence and Incidence Rates, 2017A - 2025E (in %)
Table 4 Acne Type and Treatment
Table 5 Acne Drugs Market Size and Forecast (in USD Million)
Table 6 Geographic Sales Performance, by Seven Major Markets (in USD Million)
Table 7 Acne Drugs Market, by Type (in USD Million)
Table 8 Acne Drugs Market, by Therapeutic Class (in USD Million)
表9痤疮药物市场,Administrati的模式on (in USD Million)
Table 10 Acne Drugs - U.S. Patent Expiry Schedule
Table 11 Acne Deals Landscape (2013-2018)
Table 12 Acne Product Pricing
Table 13 Acne Drugs in Development
Table 14 Late-Stage Acne Pipeline
Table 15 Pipeline Forecast - Global Acne Drugs
Table 16 Profile of Disruptive Drug: Seysara
Table 17 Profile of Disruptive Drug: CJM112
Table 18 Profile of Disruptive Drug: FMX-101
Table 19 Profile of Disruptive Drug: TWIN (S6G5T-1, S6G5T-3)
Table 20 Product Portfolio: Allergan
Table 21 Allergan Product Forecast Sales 2017A - 2025E (in USD Million)
Table 22 Allergan Pipeline View
Table 23 Allergan Catalysts and Event Calendar
Table 24 Product Portfolio: Diane-35
Table 25 Diane Product Forecast Sales 2017A - 2025E (in USD Million)
Table 26 Product Portfolio: Galderma
Table 27 Galderma Product Forecast Sales 2017A - 2025E (in USD Million)
Table 28 Galderma Pipeline View
Table 29 Product Portfolio: Stiefel
Table 30 Duac Product Forecast Sales 2017A - 2025E (in USD Million)
Table 31 Product Portfolio: Valeant
Table 32 Valeant Product Forecast Sales 2017A - 2025E (in USD Million)
Table 33 Valeant Pipeline View
Table 34 Valeant Catalysts and Event Calendar

List of Figures

Fig.1 Acne - Main Causative Factors
Fig.2 Acne - Degree of Severity
Fig.3 Current Prevalence Across Seven Major Markets - 2017
Fig.4 Current Incidence Across Seven Major Markets - 2017
Fig.5 Market Segmentation and Scope
Fig.6 Geographic Sales Performance by Seven Major Markets 2017
Fig.7 Acne Drugs Market, by Type (2017)
Fig.8 Acne Drugs Market, by Therapeutic Class, 2017A - 2025E (in USD Million)
Fig.9 Acne Drugs Market Share, by Therapeutic Class (2017)
Fig.10 Acne Sales Trend, by Mode of Administration 2017 (in USD Million)
Fig.11 U.S. Acne Drugs Market, by Type (in USD Million)
Fig.12 U.S. Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.13 U.S. Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.14 U.K. Acne Drugs Market, by Type (in USD Million)
Fig.15 U.K. Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.16 U.K. Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.17 Germany Acne Drugs Market, by Type (in USD Million)
Fig.18 Germany Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.19 Germany Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.20 Spain Acne Drugs Market, by Type (in USD Million)
Fig.21 Spain Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.22 Spain Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.23 France Acne Drugs Market, by Type (in USD Million)
Fig.24 France Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.25 France Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.26 Italy Acne Drugs Market, by Type (in USD Million)
Fig.27 Italy Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.28 Italy Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.29 Japan Acne Drugs Market, by Type (in USD Million)
Fig.30 Japan Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.31 Japan Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.32 Acne Drugs Market Share Distribution, by Company (2017A - 2025E)
Fig.33 Market Trends & Outlook
Fig.34 Market Driver Relevance Analysis (Current & Future Impact)
Fig.35 Market Restraint Relevance Analysis (Current & Future Impact)
Fig.36 SWOT Analysis (Acne Drugs Market)
Fig.37 Pipeline Assets, by Phase
Fig.38 SWOT Analysis (Allergan)
Fig.39 SWOT Analysis (Bayer)
Fig.40 SWOT Analysis (Galderma)
Fig.41 SWOT Analysis (Stiefel)
Fig.42 SWOT Analysis (Valeant)